Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct 5;73(7):e1302-e1317.
doi: 10.1093/cid/ciaa1189.

Immunosuppressive Agents and Infectious Risk in Transplantation: Managing the "Net State of Immunosuppression"

Affiliations
Review

Immunosuppressive Agents and Infectious Risk in Transplantation: Managing the "Net State of Immunosuppression"

Matthew B Roberts et al. Clin Infect Dis. .

Abstract

Successful solid organ transplantation reflects meticulous attention to the details of immunosuppression, balancing risks for graft rejection against risks for infection. The "net state of immune suppression" is a conceptual framework of all factors contributing to infectious risk. Assays that measure immune function in the immunosuppressed transplant recipient relative to infectious risk and allograft function are lacking. The best measures of integrated immune function may be quantitative viral loads to assess the individual's ability to control latent viral infections. Few studies address adjustment of immunosuppression during active infections; thus, confronted with infection in solid organ recipients, the management of immunosuppression is based largely on clinical experience. This review examines known measures of immune function and the immunologic effects of common immunosuppressive drugs and available studies reporting modification of drug regimens for specific infections. These data provide a conceptual framework for the management of immunosuppression during infection in organ recipients.

Keywords: allograft rejection; immune function assays; opportunistic infection; transplant immunosuppression; viral infection.

PubMed Disclaimer

References

    1. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351:2715–29. - PubMed
    1. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 2009; 373:1550–61. - PMC - PubMed
    1. Fishman JA. Infection in organ transplantation. Am J Transplant 2017; 17:856–79. - PubMed
    1. Vajdic CM, McDonald SP, McCredie MR, et al. . Cancer incidence before and after kidney transplantation. JAMA 2006; 296:2823–31. - PubMed
    1. Falagas ME, Manta KG, Betsi GI, Pappas G. Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review. Clin Rheumatol 2007; 26:663–70. - PubMed

MeSH terms

Substances